A CUMBRIAN dad living with motor neurone disease was among 100 people to walk 12km to raise awareness of the disease.

Objective To compare survival and to identify prognostic predictors for progressive supranuclear palsy and frontotemporal dementia. Background Progressive supranuclear palsy (PSP) and frontotemporal ...

The descriptive term of cerebral palsy encompasses the largest group of childhood movement disorders. Severity and pattern of clinical involvement varies widely dependent on the area of the central ...

Although ptosis, mydriasis and bulbar palsy are not part of the triad seen in FS, these signs have been reported to occur in both FS and BBE cases. 15 Isolated ptosis, mydriasis or oropharyngeal palsy ...

The Food and Drug Administration (FDA) has received Fast Track designation for FNP-223 for the treatment of progressive supranuclear palsy (PSP). FNP-223, previously known as ASN90, is a ...

Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord. 2020 Apr;73:105-116. doi: 10.1016/j.parkreldis.2020.04.014.

Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive ...

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases per ...

Progressive supranuclear palsy manifests in patients with symptoms such as difficulty speaking, imbalance, changes in gait, cognitive problems 2-4. PSP has a prevalence of approximately 5 cases ...